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Abbreviations and symbols 
 
δ Chemical shift 
Boc Butoxycarbonyl 




DMF Dimethylformamide  
DMP Dimethoxypropane 
DMSO Dimethyl sulfoxide  
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ESI-HRMS High resolution electrospray ionization mass spectrometry 
Et2O Diethyl ether  
EtOAc Ethyl Acetate  
EtOH Ethanol 
HOBt Hydroxybenzotriazole 
HSQC Heteronuclear Single-Quantum Correlation 
J Coupling constant 
MeOH Methanol 
NAD Nicotinamide adenine dinucleotide 
NMR Nuclear Magnetic Resonance 
PTSA p-Toluenesulfonic acid 
r.t. Room temperature 
TBAF Tetra-n-butylammonium fluoride 
TBDPS tert-Butyldiphenylsilyl 
TFA Trifluoroacetic acid  
THF Tetrahydrofuran 












This project was realized at prof. Inmaculada Robina's laboratory, Department of 





During this work, five pyrrolizidine derivatives and one isoxazolidine derivative 
have been synthetized in order to evaluate their biological activities towards 
glycosidases, related to their configurations and type of bridge functionalities 
between the bicyclic iminosugar moiety and the aromatic part of the molecules. 
The final pyrrolizidine derivatives have been synthetized through click reactions 
(urea forming reaction, thiourea forming reaction and CuAAC reaction) 
performed on a common amino-pyrrolizidine precursor. The final isoxazolidine 
derivative has been synthetized through a CuAAC reaction. In addition, an 
indolizidine scaffold was obtained through a ring-closing metathesis on a 
dialkenyl pyrrolidine. This bicyclic compound could be of interest as intermediate 
for the synthesis of indolizidine derivatives with potential as glycosidase 
inhibitors. Biological evaluation towards glycosidases of the final six compounds 
synthetized in this work revealed that all of these compounds show inhibition 
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1.1  Enzymatic inhibition: generalities1  
 
An enzyme inhibitor is a molecule that can bind to the enzyme and that decreases 
its activity. Since controlling enzymes‟ activities can regulate a metabolic 
imbalance or kill pathogens, many drugs and pesticides are enzyme inhibitors. 
The activity of an enzyme can be expressed by the velocity of the reaction that it 
catalyses, and this velocity can be affected by many factors such as temperature, 
pH, concentration of the substrate and presence of enzyme inhibitor. 
In a simple enzymatic reaction, e.g. the formation of product P from substrate S, 
the initial velocity is proportional to the concentration of the free enzyme. In most 
cases this velocity reaches a maximum value, Vmax, when all enzyme‟s molecules 
present in the medium are considered saturated from molecules of substrate. This 
kinetic model is known as classical Michaelis-Menten kinetics, whose equation 
for the initial velocity v, usually expressed in μM/min, is expressed as follows:  
  
    [ ]
   [ ]
 
The value of Km, the Michaelis-Menten constant, corresponds to the concentration 
of substrate when the velocity is half the value of Vmax.  The Michaelis-Menten 
constant Km can be used to express the affinity of the enzyme for the substrate so 
it‟s an important parameter used to characterize enzymes. The higher the value of 
Km the lower the affinity of an enzyme towards the substrate, because a high 
concentration of the latter is needed to bind half of the molecules of enzyme in the 
medium. 
Enzymatic inhibition can be classified as reversible or irreversible. Irreversible 
inhibitors bind, for example through covalent bonds, the enzyme in its active site 
and change the enzyme‟s conformation. Reversible inhibitors, on the contrary, 
bind the enzyme in a non-covalent way and, under certain conditions, the enzyme 
can recover its biological function.  
 
2 
Reversible inhibitors can be classified into three further classes, depending on 
whether they bind to the active site of the enzyme (competitives), to the enzyme-
substrate complex (uncompetitives) or both (non-competitives).  
In the competitive inhibition the inhibitors bind directly to the enzyme in the 
active site, preventing the substrate itself from binding and from reacting to form 
the products. The following equilibriums are formed (Fig. 1):  
 
Fig. 1 Equilibriums in competitive inhibition. E = free enzyme, S = substrate, I = inhibitor, ES = enzyme-
substrate complex, EI = enzyme-inhibitor complex, P = product. 
In this type of inhibition the value of Vmax remains constant while an apparent 
increase of the value of Km is observed. (Fig. 2) 
  
Fig. 2 Lineweaver-Burk representation for competitive inhibition  
In uncompetitive inhibition the molecule of inhibitor binds to the enzyme-
substrate complex, avoiding the formation of the final products. This type of 




Fig. 3 Equilibriums in uncompetitive inhibition. E = free enzyme, S = substrate, I = inhibitor, ES = 
enzyme-substrate complex, ESI = enzyme-substrate-inhibitor complex, P = product. 
 
An uncompetitive inhibitor modifies both Km and Vmax values, both resulting 
lower than in the enzyme without inhibition. (Fig. 4) 
 
Fig. 4 Lineweaver-Burk representation for uncompetitive inhibition 
Non-competitive inhibitors bind reversely to the enzyme, usually not in its active 
site but in other regions, so that this binding can occur both with the free enzyme 
and with the enzyme-substrate complex (Fig. 5). 
 
Fig. 5 Equilibriums in non-competitive inhibition. E = free enzyme, S = substrate, I = inhibitor, ES = 





The non-competitive inhibition does not change the value of Km, but a decreasing 
of the value of Vmax is observed. (Fig. 6) 
 
Fig. 6 Lineweaver-Burk representation for noncompetitive inhibition 
      
 
5 
1.2  Glycosidases  
 
Glycosidases, or glycoside hydrolases, are enzymes that catalyse the hydrolysis 
and the formation of glycosidic bonds. Glycosidases can catalyse the hydrolysis of 
O-, N- and S- glycosides, leading to the formation of a sugar hemiacetal or 
hemiketal and their corresponding free aglycone. The hydrolysis of carbohydrates 
is a very common and widespread biological phenomenon in living systems
2
, and 
it can be found essentially in every domain of life, thus the control of this activity 
can play a key role in treating many diseases.  
For example, some glycoside hydrolases are involved in the processing and 
biosynthesis of N-link glycoproteins in the Golgi apparatus and in the 
endoplasmic reticulum.
3
 Cancerous tumours can express unusual carbohydrate 
structures resulting from an abnormal function of this biosynthesis, and the 
inhibition of some of these glycosidases, such as Golgi α-mannosidase II, has 
shown a certain potential in cancer treatment.
4
 
It is also known that α-L-fucosidase activity and fucose-residue levels are related 
to many disorders, such as fucosidosis, inflammation, cancer and cystic fibrosis.
5
  
Type II diabetes can also be controlled using glycosidase inhibitors, which can 







1.2.1  Mechanisms of glycosidase catalysed hydrolysis  
 
The majority of the glycosidase enzymes acts through an acid/base catalysed 
mechanism via an oxocarbenium ion-like transition state. In particular, these 
mechanisms can be divided in two main categories: hydrolysis of the glycosidic 
bond with inversion of configuration, and hydrolysis of the glycosidic bond with 
retention of configuration; so that mechanistically speaking glycosidases can be 
divided into inverting enzymes and retaining enzymes. Two likely mechanisms for 
this type of enzymes were first proposed by Koshland
7
 and, despite some 
refinements, they are still consider valid nowadays.  
It is known that inverting glycosidases act through a single-step mechanism in 




Scheme 1. Inverting mechanism for a generic β-glycosidase 
 
An active site‟s aminoacid acts as a general base helping to deprotonate a water 
molecule while another amino acid, that behaves as a general acid, protonate the 
oxygen activating the leaving OR group of the substrate; the process then pass 
through an oxocarbenium-like transition state and finally the glycolysis products 
are released.
8
 In most of the known cases, these acid and base groups are the side 
acid chains of glutamic or aspartic acid residues in the active site. The 
 
7 
oxocarbenium-ion character of the transition state is supported by several kinetics 
studies.  
On the other hand, the mechanism with retention of configuration it is 
hypothesized to be a double displacement mechanism, via a covalent glycosyl-
enzyme intermediate (scheme 2). 
Scheme 2. Retaining mechanism for a generic α-glycosidase 
 
Each of the two steps of this process passes through an oxocarbenium ion-like 
transition state, as in the inverting mechanism. This process is catalysed mainly by 
two amino acids, one acting as a nucleophile and the other acting as acid/base, 
depending on the step. In this mechanism, as in the previous one, the two catalytic 
groups are commonly the side acid chains of aspartic and glutamic residues in the 
active site.  
In the first step, the amino acid that act like a nucleophile attacks the anomeric 
centre of the substrate while the other residue acts as an acid catalyst protonating 
the glycosidic oxygen, so that the glycosyl-ester intermediate is formed as the 
 
8 
glycosidic bond cleaves. At this point, the ROH molecule, that formed the aglycon 
part, leaves the active site and it is replaced by a water molecule. In the second 
step, the conjugated base of the residue, which previously acted as an acid, 
deprotonates the water molecule that attacks the anomeric centre and cleaves the 




Even though the classical inverting and retaining mechanisms are the most 
common in this class of enzymes, several different variation of these mechanisms 
and a substantially different one, that catalyses the reaction with a NAD cofactor, 
are also known.  
For instance, some glycosidase substrates that contain an N-glycolyl or N-acetyl 
group at position 2 act through a variation of the retaining mechanism, with 
neighbouring group participation. These enzymes do not have a catalytic 
nucleophile in the active site, rather the 2-acetamido group acts as an 




In some other retaining glycosidases, it was found that the hydrolysis of the 
glycosidic bond requires a NAD cofactor that remains bonded to the enzyme 
throughout the catalysis. The mechanism starts with an initial oxidation of the 
hydroxyl at position 3 of the substrate by the NAD-enzyme complex, then an 
elimination reaction and a water addition at the anomeric centre, followed by a 
final reduction of the ketone previously formed, generate the final products.
11
 
Even though this mechanism acts through an elimination and redox reactions the 




1.3  Glycosidase inhibitors  
Due to the widespread biological roles that glycosidases have in living organisms, 
glycosidase inhibitors can have many applications in the agrochemical and 
pharmaceutical fields. 
For example, Validoxylamine A (Fig.7) is a powerful inhibitor of trehalases in R. 
solani and other organisms, and is a product of the metabolism of Validamycin A 
(Fig. 7), a substance commercialized from Takeda Chemical Industries for the 




Fig.7 Chemical structures of Validoxylamine A (1) and Validamycin A (2) 
 
In the therapeutical field glycosidase inhibitors have been found to have many 
applications as drugs in a broad spectrum of diseases. 
For instance, in the „70s it was realized that inhibition of pancreatic α-amylase and 
other intestinal disaccharidases could regulate the absorption of carbohydrates, 
and thus began the search of inhibitors that could be used as a treatment in non-
insulin-dependent diabetes mellitus (Type II).4 This is the case, for instance, of 




Fig. 8 Chemical structure of Acarbose (3), Salacinol (4) and Kotalanol (5), inhibitors of α-glucosidases. 
Acarbose is a potent sucrose inhibitor that was found to be effective in rats and 
healthy human volonteers.
12
 In 1990, after clinical development, Arcarbose 
(Glucobay™) was introduced onto the market in Germany for the treatment of 
diabetes and was successively commercialized in Europe, Latin America and 
USA.4 
On the other hand, salacinol and kotalanol were found to be the α-glucosidase-
inhibiting components of the ayurverdic traditional medicine used to treat 
diabetes.
13
 The inhibitory activity of salacinol is almost equal to that of acarbose 
toward maltase and sucrase but is higher toward isomaltase.
14
 Kotalanol shows a 
more potent inhibitory activity than acarbose and salacinol toward sucrose.13 The 
efficacy of these compounds as inhibitors of glycosidases is probably due to the 
permanent positive charge of the sulfonium, that can mimic the positive charge of 
the transition state in the glycosidase-mediated hydrolysis reaction.
15
 
Chemically speaking, one of the most important family of glycosidase inhibitors 




1.3.1 Iminosugars as glycosidase inhibitors 
Iminosugars, or azasugars, are structural analogues of carbohydrates where the 
oxygen in the ring is replaced with a nitrogen atom and many of them inhibit 
glycosidases in a reversible and competitive manner.
4
  
Many examples of naturally occurring mono- and bicyclic iminosugars are known 
to be glycosidase inhibitors, such as swainsonine (6) and 1,4-dideoxy-1,4-imino-
D-arabinitol  (D-AB1) (7) (Fig. 9) 
 
Fig. 9 Chemical structure of the naturally occurring glycosidase inhibitors swainsonine (6) and D-AB1 (7). 
 
Swainsonine (6) is an indolizidine alkaloid that is also a Golgi α-mannosidase II 
inhibitor; it has shown potential in being a drug for patients with tumours, since it 
leads to significant reduction in tumour masses in human patients.
16
 
D-AB1 (7), originally isolated from a fruit, is a potent inhibitor of glycogen 




Due to their biological activity towards glycosidases, iminosugars were broadly 
investigated in order to discover pharmacological applications. For example, 
miglitol (Glyset™) (Fig. 10) is an oral anti-diabetic drug, used in treatment of type 
II diabetes, that works inhibiting α-glucosidases.4
 
 
Fig.10 Chemical structure of miglitol (8) 
 
12 
Iminosugars are believed to act as inhibitors towards glycosidases mimicking the 
oxocarbenium ion-like transition state of the enzyme-catalyzed O-glycoside 
hydrolysis; the electrostatic interaction between the protonated N at physiological 
pH and the active site of the enzyme is a possible mechanism to explain these 
inhibitions.
18
 For example, nojirimycin (9) (Fig. 11) is very similar to glucose. 
The protonated inhibitor (10) mimics the charge development that occurs in the 
transition state of the cleavage mechanism of glycosidases, but has a chair 
conformation and not the half-chair conformation that is believed to be the 
conformation of the transition state (11).18
 
(Fig. 11)  
 
Fig. 11 Structures of nojirimycin (9), protonated nojirimycin (10) and representative transition state of a 
glucosidase-catalyzed reaction (11) 
However, many iminosugars lack selectivity toward a single glycosidase and 
normally have poor membrane permeability. Those are drawbacks that can limit 
their pharmacological application. 
It is also known that while the glycone part of the inhibitor occupies the active 
site, the aglycone part makes additional interactions with amino acids of the 
allosteric site of the enzyme that can increase the affinity of the enzyme for the 
inhibitor or induce a fit of the glycone in the active site.
19
 
For these reasons many studies focus on structural modification of known 
glycosidase inhibitors in order to discover more potent and selective alternatives.  
For example, many natural occurring polyhydroxylated pyrrolizidine are known to 




Fig.12 Chemical structures of casuarine (12) and australine (13) 
 
Casuarine (12) is a potent inhibitor of amiloglucosidase of Aspergillus niger 
(IC50=0.7 μM) but is not specific because it shows also inhibition activity towards 
other α- and β-glucosidases.
20
 Australine (13) is also an inhibitor of 
amiloglucosidase but also shows potent inhibition towards α-glucosidase of 





 have developed synthetic strategies to obtain 
polyhydroxylated pyrrolizidines, modifying number and configuration of 
stereogenic centres in the pyrrolizidine moiety. However, fewer studies focus on 
the incorporation of substituents of different nature in the pyrrolizidine moiety. 
Recently, Toyooka and cols. described the preparation of many pyrrolizidines 
derivatives with different aliphatic chains at position C-3
23
, finding a selective 
inhibitor of α-fucosidase in compound 14 (IC50= 34 μM) (Fig. 13). 
At the same time, Fleet and cols.
24
 described the synthesis of fluorinated 
pyrrolizidine, derived from australine. Compound 15 (Fig. 13), among others, 
showed more potent inhibition (IC50=0.63μM) towards α-glucosidase of A. niger 
than australine and also moderate inhibition towards trehalase. 
 
Fig. 13 Chemical structures of compound 14, 15 and 16, pyrrolizidine-derivatives glycosidase inhibitors 
 
14 
The discovery of a potent coffee bean α-galactosidase inhibitor (IC50= 0.37 μM), 
compound 16 (Fig.13), that has also shown inhibition for human lysosomal α-
galactosidase (IC50= 5.3 μM)
25






2. Aim of the thesis  
 
Given the well-known properties of several bicyclic iminosugar derivatives as 
glycosidase inhibitors, the aim of this thesis was to synthesize some molecules of 
this class in order to evaluate their biological activity relate to their structure. 
The main part of this thesis consisted in the synthesis of different hydroxylated 
pyrrolizidine derivatives, starting from L-Arabinose, and in the evaluation of their 
biological properties as glycosidase inhibitors (Scheme 3). This project was 
realized at the Department of Organic Chemistry, Faculty of Chemistry, 




It has been observed how differences in molecular structures, such as C-6 
configuration and the type of bridge-functionalities between the pyrrolizidine 
scaffold and the aromatic group, modify the values of enzymatic inhibition. This 
evaluation will be useful to choose the best leads to further carry out parallel 
synthesis of urea/thiourea or triazole derivatives trough reaction of 17 with a small 
library of isocyanates/isothiocyanates or alkynes. The in situ biological evaluation 
of this library
26
 will allow the rapid identification of the best inhibitor on which 
conduct more accurate inhibition studies. 
 
In addition, an isoaxozoline derivative, with a triazole bridge-functionality, was 
synthesized in order to evaluate its biological properties as glycosidase inhibitor 







Lastly, starting with an intermediate that had already been synthetized from D-
mannose, the focus was to obtain the indolizidine scaffold through a ring-closing 
metathesis on a dialkene, in order to get to molecules further derivatized and 




The reaction of ring closing metathesis was performed using a Ruthenium Grubbs 
catalyst of second generation. This indolizidine-derivative compound could be 






3. Results and discussion 
 
3.1 Synthesis of the pyrrolizidine derivatives. 
 
In the first part of this project different hydroxylated pyrrolizidine derivatives 
(26a,b, 27, 28a,b, Fig. 14) have been synthesized following a procedure optimized 





Fig. 14 Structure of the final compounds 26a,b, 27 and 28a,b 
 
These compounds have different bridge-functionalities (urea, thiourea and 
triazole) between the iminosugar and the aromatic group that are formed through 
“click reaction” on amino-pyrrolizidines 17, prepared from L-arabinose as starting 
material. 
The synthetic pathway starts with the synthesis of protected eritrose 29 from L-
arabinose.
27
 First, L-arabinose was protected at position 3 and 4 using 2,2-DMP; 
then, compound 29 was obtained through periodate cleavage in 73% yield. Then, 
nitrone 19 was synthesized, following the procedure previously described by 
Goti,
28
 passing through an oxime-intermediate and it was obtained in 25% yield. 
 
18 
The 1,3-dipolar cycloaddition between the nitrone 19 and the protected allylic 








Treatment of isoxazolidine 31 with TBAF in THF formed compound 18, with its 
alcoholic function deprotected, with a yield of 95%, the latter was subsequently 
tosylated to achieve compound 22. This compound was then submitted to a 
hydrogenation with Pd/C, obtaining pyrrolizidine 32 through the reductive 
cleavage of the N-O bond and the subsequent cyclization.
29





The formation of amines 17, precursors of the final compounds, was performed in 
two steps: first, alcohol 32 was submitted to a Swern oxidation in order to obtain 
ketone 33, that gave pyrrolizidines 17 via reductive amination, following a 
procedure similar to that described by Miriyala and cols.
30





Pyrrolizidine 17 was obtained as a 2:1 mixture of diastereomers, by reductive 
amination. This reaction consisted in treating the ketone with NH3 in the presence 
of Ti(O
i
Pr)4, and then reducing the imine-intermediate in situ using NaBH4. 
Amino-thioureas 34a and 34b were formed treating pyrrolizidines 17 with 1-
isothiocyanato-3,5-bis(trifluoromethyl)benzene and were separated using a 
chromatographic column, obtaining 34a with a yield of 23% and 34b with a yield 
of 54%. Finally, the deprotection of the acetal function of 34a and 34b carried out 
in acidic medium led to the final compounds 26a and 26b respectively with 61% 






Similarly, amino-ureas 35a and 35b were formed treating pyrrolizidines 17 with 
1-isocyanato-3,5-bis(trifluoromethyl)benzene at 0°C, but the yield of this reaction 
was rather low. Several by-products were formed, probably due to the more 
reactive nature of isocyanates compared to isothiocyanates, even if the reaction 
was performed at 0°C and conducted for a shorter period of time. Compound 35a 
and 35b were formed  in 2% and 15% yield respectively; finally, by the treatment 
of 35b in acidic medium, the deprotected amino-urea 27 was obtained with a yield 




 Scheme 10 
 
On the other hand, the synthesis of compounds 28a and 28b was carried out 
following a one-pot procedure described by Chiara and cols.
31
 Initially,  
pyrrolizidines 17 were converted into azides by reaction with NfN3. Then a 
copper(I)-catalyzed azide alkyne cycloaddition reaction (CuAAC) with 1-ethynyl-
3,5-bis(trifluoromethyl)benzene, where Cu
2+
 is reduced to Cu
+
 in situ using 
sodium ascorbate, followed by chromatographic purification, afforded triazoles 
derivatives 36a and 36b in 15% and 43% yields, respectively. Finally, 
deprotection in acidic medium of compounds 36a and 36b gave the 
dihydroxylated triazole derivatives 28a and 28b in 66% and 70% yields 




 Scheme 11 
 
Configurations of all the diastereomers were assigned and confirmed comparing 
experimental 
1




3.2 Synthesis of the isoxazolidine derivative. 
 
After obtaining pyrrolizidine derivatives 26a,b, 27, and 28a,b, the triazole-
isoxazolidine derivative 20 was synthesized in order to evaluate its inhibition 
towards glycosidases.  
This molecule has been synthesized through a CuAAC reaction on azide 21, 





First, tosylate derivative 22 was treated with NaN3 in DMF obtaining compound 
21 in  73% yield. Secondly, from this compound, through a CuAAC reaction with 
1-ethynyl-3,5-bis(trifluoromethyl)benzene in presence of CuI and DIPEA, 
isoxazolidine derivative 37 was obtained with an excellent 96% yield. 
Finally, acidic deprotection of compound 37 led to the formation of the 




3.3 Ring-closing metathesis to indolizidine scaffold.  
 
The aim of the last part of the project was to obtain an indolizidine scaffold 
through the reaction of ring closing metathesis of alkenes. This synthetic pathway 
















In the first step, diol 23 was first treated with I2, PPh3 and imidazole in dry toluene 
at 80°C,
33
 obtaining the alkene 38 with a yield of 37%. This compound was found  
to be quite volatile so the poor yield could be explained from its partial 
evaporation during the removal of toluene and the difficult separation of the 
remaining PPh3 and its oxide 
Secondly, compound 38 was treated with a solution of trifluoroacetic acid (TFA) 
in CH2Cl2 at 20% concentration, removing selectively the Boc protecting group of 
the amine. After the deprotection, the crude reaction was submitted, without 
purification, to an acylation with 3-butenoic acid, EDCI, HOBt and two equivalent 
of Et3N (in excess in order to neutralize the TFA left from the previous step). 
After the chromatographic separation, the overall yield of the two steps was 63%. 
Compound 24 was obtained as a mixture of two stable rotamers, as has been 
observed in the NMR spectra, and this is a common characteristic for this class of 
amide-compounds. In fact, in the 
1
H-NMR spectrum, acquired at room 
temperature, the multiplicity of the signals was too complex to be determined and 
in the 
13
C-NMR almost every signal was split for the two conformers.  
Lastly, second generation Grubb‟s Catalyst (0.14 equiv.) was added to the 
dialkene 24, diluted in dry CH2Cl2, and the mixture was heated at 60°C overnight 
obtaining compound 25 in 74% yield. 
 
Starting from this bicyclic compound, with the purpose of obtaining possible 
glycosidase inhibitors, further steps could be the epoxidation of the double bond 
(stereoselectivity should be studied), the opening of the epoxide with an azide (its 
regio- and stereoselectivity should be studied) and a further CuAAC on the newly 









3.4 Biological evaluation 
The enzymatic inhibition of the final compounds 26a,b, 27 28a,b and 20 has been 
measured towards eleven commercially available glycosidases: β-galactosidases 
from Aspergillus oryzae and from Escherichia coli, α-glucosidase from rice, α-
mannosidase from Jack beans, β-N-acetylglucosaminidase from Jack beans, α-
galactosidase from coffee beans, amyloglucosidase from Aspergillus niger, α-
glucosidase from Saccharomyces cerevisiae, β-glucosidase from almonds, β-
mannosidase from snail and α-fucosidase from H. sapiens. 
None of the compounds shows signs of inhibition with respect to nine of the 
eleven tested enzymes, thus they show inhibition only for the almonds‟ β-
glucosidase and the jack beans‟ α-mannosidase. 
The following table (Table 1) shows the percentages of inhibition measured for 
each compound at 0.5 mM concentration of the inhibitor and the value of IC50 is 
reported only for the more active ones. 
Table 1. Inhibitory activities of compounds 26a,b, 27, 28a,b and 20 towards glycosidases. % Inhibition at 










(IC50 = 98 μM) 
 










(IC50 = 142 μM) 
 
22 % no inhibition 
 
Values of IC50 (concentration of inhibitor at which the enzymatic activity is 50% 
inhibited) were calculated only for 26b, 28a and 28b inhibiting jack beans‟ α-
mannosidase. For each of these compounds a curve „% of inhibition/concentration 
of inhibitor (mM)‟ was plotted and the value of IC50 was obtained from the curve 






Figure 15. %Inhibition/[inhibitor] plots for compounds 26b, 28a and 28b. 
Even though the values of inhibition of these compounds are not particularly high 
(IC50 ≈100-200 μM), most of them show selectivity for a single enzyme. 
The most interesting results as inhibitors, in terms of potency and selectivity, are 
those of compounds 26b and 28b. A strategy to find new and better glycosidase 
inhibitors could be the evaluation of the biological activity of molecules with 
same configuration in the glycone part and same bridge functionalities as in 26b 
and 28b, but with different aromatic parts.  
 
29 
The thiourea-compound 26b shows inhibition only for α-mannosidase with a 
percentage of 87% (IC50 = 98 μM). When the thiourea functionality is exchanged 
with the urea one, as in compound 27, a decrease in selectivity is observed, 
because compound 27 inhibits α-mannosidase at 56% but also the β-glucosidase 
enzyme at 38%. 
The thiourea-compound 26a, where the C-6 configuration is opposite to that in 
compound 26b, only shows  inhibition for the β-glucosidase, with a percentage of 
59%, as opposed to compound 26a, that inhibits α-mannosidase. 
For what concerns the triazole-compounds, the major diastereomer 28b only 
shows inhibition for α-mannosidase at 75% (IC50 = 142 μM) whereas the minor 
28a shows a lower selectivity with 73% of inhibition (IC50 = 286 μM)  for α-
mannosidase and also a weak inhibition (27%) for β-glucosidase.  
Compound 20 shows only a weak inhibition of 22% for β-glucosidase; this 
compound has some structure similarity with compound 28a but has an oxygen in 
the cycle and an additional CH2 before the triazole that change the orientation of 
the aglycone and these changes involve the loss of inhibition for α-mannosidase. 
We can also observe, knowing the inhibition values for ent-26a, ent-26b, ent-27, 
ent-28a and ent-28b
25
 that there is a general trend of this enantiomers to be more 
potent but also slightly less selective than the ones synthesized in this work. 
Another difference is that the enantiomers show inhibition for α-galactosidase, α-
mannosidase and α-fucosidase, while the compounds presented in this thesis 




4. Conclusions  
During this work, five pyrrolizidine derivatives, compounds 26a,b, 27 and 28a,b 
and one isoxazolidine derivative, compound 20, have been synthetized. The 
biological evaluation of these compounds was conducted in order to relate their 
configurations and type of bridge functionalities between the bicyclic iminosugar 
moiety and the aromatic part of the molecules, to their inhibition activities towards 
glycosidases. All the final compounds synthesized in this work show inhibition 
towards almonds‟ β-glucosidase and/or jack beans‟ α-mannosidase; the best 
results in term of potency and selectivity are those of compound 26b (jack beans‟ 
α-mannosidase, IC50 = 98 μM) and 28b (jack beans‟ α-mannosidase, IC50 = 142 
μM). A strategy to find new and better glycosidase inhibitors could be the 
evaluation of the biological activity of molecules with same configuration in the 
glycone part and same bridge functionalities as in 26b (thiourea) and 28b 
(triazole), but with different aromatic parts. 
A compound with indolizidine scaffold, compound 25, was obtained through a 
ring-closing metathesis on a dialkenyl pyrrolidine. This bicyclic compound could 
be of interest as intermediate for the future synthesis of indolizidine derivatives 





5. Experimental section 
 
5.1 Materials 
All the reactants used, if not differently indicated in the synthesis section, were 
commercially available.   
 
5.2 Experimental methods and Instrumentation 
For the reactions conducted under inert atmosphere were used N2 “U” commercial 
quality and Ar “N-48” commercial quality. 
Solvent evaporation was performed under reduced atmosphere at temperatures 
below 50°C. 
For chromatography the following stationary phases were utilized: 
 Silica gel 60 (Merck Kiesekger 60 F254 or Kieselgel 60 F254, 0.2 mm thick) 
for TLC 
 Silica gel 60 (E. Merck, particle size 0.043-0.063 and 0.063-0.200 mm) for 
chromatography under gravity or compressed air. 
The optical rotations ([α]D) were measured with a spectropolarimeter Jasco P-
2000, using the sodium emission line (λ = 589 nm) in a 1 cm-long cell, and at the 




C-NMR spectra were acquired with instruments Bruker AMX 300 
of the General Service of the University of Seville (CITIUS). The solvents used 
were CDCl3 and CD3OD at room temperature. The values of chemical shift (δ) are 
given in ppm and calibrated with the solvent signals; the values of coupling 
constants (J) are given in Hz. The assignation of each signal was confirmed and 




The ESI (ElectroSpray Ionization) mass spectra were performed with Micromass 
AutoSpeQ instrument of the general service of the University of Seville. For each 
experiment, the value of m/z registered is compared, up to the fourth decimal, 










To a solution of L-Arabinose (10 g; 67 mmol) in DMF (140 mL) 2,2-DMP (34 
mL, 266.4 mmol) and PTSA (0.259 g, 1.33 mmol) are added, and the obtained 
solution is then stirred at room temperature. After 4 hours Na2CO3 is added until 
the pH was neutral, the solution is filtered and concentrated. The crude is then 
dissolved in H2O and washed several times with cyclohexane. After that, NaIO4 
(17g, 80 mmol) is added to the aqueous phase and the solution is stirred at room 
temperature for 2.5 hours. Later, NaOH 1 M is added to the solution until the pH 
is higher than 7 and the solution is stirred during 1 hour at room temperature. 
Finally, HCl 1 M is added to neutralize the solution and the aqueous phase is 
extracted several times with EtOAc. The organic phases are reunited, dried over 
Na2SO4, filtered and concentrated. The resulting crude is purified by  column 
chromatography on silica gel (Et2O/Cyhex 2/1 → 1/1→ 2/1) obtaining compound 











To a solution of 29 (6.42 g, 40.1 mmol) 0.5 M in dry pyridine (70 mL),  molecular 
sieves of 3 Å (35 g) and NH2OH·HCl (3.34 g, 48.1 mmol) are added. The 
resulting solution is stirred at room temperature under inert atmosphere for 17 
hours. After that time, the solution is cooled at 0°C and a solution of MsCl (4.2 
mL, 43 mmol) in dry pyridine (70 mL) is added rapidly. The solution is stirred at 
room temperature under inert atmosphere for 24 hours. Finally, the reaction 
mixture is diluted with CH2Cl2, filtered on celite and washed several times with 
CH2Cl2 and EtOAc. The resulting crude is then purified by a column 
chromatography on silica gel (EtOAc/MeOH 15/1  10/1) and compound 19 
(1.60 g, 10.2 mmol, 25%) is obtained as a pale yellow solid. 
 
Data for compound 19: 
 29Dα           28.26 (c 0.500, CH2Cl2) 
 














To a solution of allylic alcohol (3.0 g, 52.5 mmol) and imidazole (4.2 g, 63 mmol) 
in dry DMF (65 mL) cooled to 0°C, TBDPSCl (15.1 mL, 56.85 mmol) is added. 
The reaction is stirred at r.t. under inert atmosphere for one day. After that time, 
the mixture is cooled to 0°C and 75 mL of water are added. The phases are 
separated and the aqueous phase is extracted with EtOAc. The combined organic 
phases are washed with water and with brine, dried over Na2SO4, filtered and 
concentrated. The resulting crude is purified by a column chromatography on 
silica gel (EtOAc/Cyhex 1/50) obtaining compound 30 (14.01 g, 47.2 mmol, 90%) 









A solution of 19 (2.83 g, 18.0 mmol) and 30 (10.65 g, 36.0 mmol) in toluene (217 
mL) is stirred at reflux for 5 hours. After that time, the reaction mixture is cooled 
until room temperature is reached and the solution is concentrated. The resulting 
crude is then purified by a column chromatography on silica gel (EtOAc/Cyhex 
1/5) and compound 31 (5.95 g, 13.1 mmol, 73%) is obtained as a colourless oil. 
 
Data for compound 31: 
 29Dα           -21.25 (c 0.845, CH2Cl2) 
 













To a solution of 31 (2.709 mmol) in THF (22.7 mL) a solution of TBAF 1M in 
THF (3.0 mL, 3.0 mmol) is added; the reaction mixture is stirred at room 
temperature for 2 hours, and then, mixture is concentrated. The resulting crude is 
purified by a column chromatography on silica gel (Et2O → Et2O/MeOH 9/1) 
obtaining compound 18 (554 mg, 2.57 mmol, 95%) as a white solid. 
 
Data for compound 18: 
 27α D           -42.0 (c 0.330, CH2Cl2) 
 













Compound 18 (2.44g, 11.3 mmol) is dissolved in 90 mL of dry CH2Cl2 under inert 
atmosphere and are cooled to 0°C. After that, Et3N (7.9 mL 56.5 mmol) is added 
dropwise and then TsCl (6.46 g, 33.9 mmol) is added. The reaction mixture is 
stirred at r.t. for 4 h. After that time, the reaction mixture is cooled to 0°C and 25 
mL of water are added dropwise, the resulting mixture is left stirring for 15 
minutes. The organic phase is then washed with water and with brine, dried over 
Na2SO4, filtered and concentrated. The crude is purified by a column 
chromatography on silica gel (EtOAc/Cyhex 2/1 → EtOAc/Cyhex 1/2) and 
compound 22 (2.99 g, 8.09 mmol, 72%) is obtained as a white solid. 
Data for compound 22: 
 
 26α D           -43.75 (c 0.240, CH2Cl2) 
 












Compound 22 (2.99 g, 8.12 mmol) is dissolved in 160 mL of MeOH, and a 
catalytic quantity of Pd/C is added to the reaction mixture. The flask is then 
saturated with H2 at 1 atmosphere and the reaction is stirred during 4 hours at r.t. 
The reaction mixture is then concentrated and the crude is purified with a 
chromatographic silica column (EtOAc/MeOH 3/1 → EtOAc/MeOH 1/2) 
obtaining compound 32 (1.21 g, 6.09 mmol, 75%) as a white solid. 
 
Data for compound 32: 
 
 30Dα                    23.12 (c 0.950, CH2Cl2) 












A solution of oxalyl chloride (1.0 mL, 12.2 mmol) in dry CH2Cl2 (15 mL) is 
cooled to -78 °C and then dry DMSO is added (1.7 mL, 24.4 mmol). The mixture 
is left reaching -65°C, then a solution of compound 32 (1.21 g, 6.09 mmol) in dry 
CH2Cl2 (19 mL) is added and the reaction mixture is stirred for 5.5 h at -65°C 
under inert atmosphere. After that time, Et3N (4.2 mL, 30.4 mmol) is added 
dropwise, the reaction is left reaching r.t. and then is concentrated. The resulting 
crude is purified by a column chromatography on silica gel (Et2O/Acetone 3/1) 
and compound 33 (0.68 g, 3.47 mmol, 57%) is obtained as an orange solid. 
 
Data for compound 33: 
 30Dα                    146.44 (c 0.550, CH2Cl2) 













A solution of compound 33 (684 mg, 3.47 mmol) and Ti(O
i
Pr)4 (2.0 mL, 6.9 
mmol) in 25 mL of EtOH is saturated with gaseous NH3 at one atmosphere and 
the reaction mixture is stirred for 4.75 h at r.t. After that time, NaBH4 (197 mg, 
5.20 mmol) is added and the reaction is stirred for 2 h. Then, 18 mL of NH4OH 
2M are added and the mixture is filtered using celite, washed many times with 
EtOH and AcOEt and concentrated. The resulting crude is purified by  column 
chromatography on silica gel (DCM/MeOH/NH4OH 7/1/0.05 → 5/1/0.05) 
obtaining, as a mixture of diastereoisomers (2:1), compound 17 (510 mg, 2.57 
mmol, 74%) as a pale yellow oil. 
 
Data for compound 17: 















             
 
To a solution of 17 (158 mg, 0.795 mmol) in 8 mL of dry CH2Cl2, under inert 
atmosphere, 1-isothiocyanate-3,5-bis(trifluoromethyl)benzene (370 μL, 1.99 
mmol) is added. The reaction mixture is stirred at r.t. for 3.75 h and then is 
concentrated. The resulting crude is then purified by column chromatography on 
silica gel (DCM/MeOH 40/1 → 20/1) obtaining compound 34a (86 mg, 0.180 
mmol, 23%) and compound 34b (201 mg, 0.428 mmol, 54%) as white solids. 
Data for compound 34a: 
 23Dα                    33.14 (c 0.6, CH2Cl2) 
ESI-HRMS  m/z obsd. 470.1324, calculated for C19H22F6N3O2S [M+H]
+
: 470.1331 
The NMR data of compound 34a are the same of the data of its enantiomer.25 
 
Data for compound 34b: 
 23Dα                    31.00 (c 0.73, CH2Cl2)
 
ESI-HRMS  m/z obsd. 470.1323, calculated for C19H22F6N3O2S [M+H]
+
: 470.1331 










             
 
 
Compound 17 (0.160 g, 0.81 mmol) is dissolved in H2O (1.1 mL) and MeOH (2.9 
mL), and NaHCO3 (0.271 g, 3.23 mmol), a solution of NfN3 (0.471 g, 1.45 mmol) 
in Et2O (2.2 mL) and CuSO4·5H2O (20 mg, 0.081 mmol) are added. The reaction 
is stirred at r.t. during 6 h, then 1-ethynyl-3,5-bis(trifluoromethyl)benzene (0.211 
g, 0.89 mmol,) and sodium ascorbate (0.240 g, 1.21 mmol) are added. The 
reaction mixture is stirred overnight at r.t. After that time, the reaction mixture is 
concentrated, redissolved in CH2Cl2 and then washed with a saturated solution of 
NaHCO3 in water. The organic phase is dried over Na2SO4, filtered and 
concentrated. The resulting crude is purified by a column chromatography on 
silica gel (Et2O/Acetone 15/1 → 4/1) obtaining compound 36a (56 mg, 0.12 
mmol, 15%) and compound 36b (158 mg, 0.34 mmol, 43%) as pale yellow oils. 
Data for compound 36a: 
 23Dα                    7.20 (c 0.53, CH2Cl2) 








Data for compound 36b: 
 29Dα                    37.07 (c 0.97, CH2Cl2) 













             
 
To a solution of compound 17 (0.153 g, 0.77 mmol) in dry CH2Cl2 (8.3 mL) at 0 
°C 1-isocyanate-3,5-bis(trifluoromethyl)benzene (0.217g, 0.85 mmol) is added 
dropwise. The reaction is stirred for 1 h at 0°C under inert atmosphere. After that 
time the mixture is concentrated and then purified by a column chromatography 
on silica gel (DCM/MeOH 20/1 → 10/1 ) obtaining compound 35a (8 mg, 0.02 
mmol, 2.2%) and compound 35b (0.52 mg, 0.11 mmol, 15%) as white solids.  
 
Data for compound 35a: 
 30Dα                    32.79 (c 0.77, CH2Cl2) 




The NMR data are consistent with those of its enantiomer.25 
Data for compound 35b: 
 30Dα                    25.24 (c 0.765, CH2Cl2) 








General procedure for acidic deprotection: 
A solution of the protected compound (0.5 mmol) in 12 mL of a mixture of HCl 
4M/ THF (1/1) is stirred at r.t. for 3.5 h. After that time, the reaction mixture is 
concentrated and the residue is dissolved in 9 mL of THF, neutralized with 7 mL 
of NH4OH (25%) and concentrated. The crude is then purified by column 







Following the general procedure for acidic deprotection on 34b (0.122 g, 0.26 
mmol) and purification through column chromatography on silica gel 
(DCM/MeOH/NH4OH 5/1/0.01) compound 26b (91 mg, 0.212 mmol, 81%) is 
obtained as a white solid. 
Data for compound 26b: 
 29Dα                    14.52 (c 0.65, MeOH) 














Following the general procedure for acidic deprotection on 34a (0.073g, 0.15 
mmol) and purification through column chromatography on silica gel 
(DCM/MeOH/NH4OH 5/1/0.01) compound 26a (41 mg, 0.94 mmol, 61%) is 
obtained as a white solid. 
Data for compound 26a: 
 29Dα                    -10.98 (c 0.65, MeOH) 













Following the general procedure for acidic deprotection on 36b (0.148 g, 0.32 
mmol) and purification through column chromatography on silica gel 
(DCM/MeOH/NH4OH 5/1/0.02) compound 28b (95 mg, 0.22 mmol, 70%) is 
obtained as a white solid. 
Data for compound 28b: 
 29Dα                    20.03 (c 0.61, MeOH) 













Following the general procedure for acidic deprotection on 36a (0.046 g, 0.10 
mmol) and purification through column chromatography on silica gel 
(DCM/MeOH/NH4OH 8/1/0.01) compound 28a (28 mg, 0.06 mmol, 66%) is 
obtained as a white solid. 
Data for compound 28a: 
 29Dα                    -6.73 (c 0.695, MeOH) 













Following the general procedure for acidic deprotection on 35b (0.035 g, 0.07 
mmol) and purification through column chromatography on silica gel 
(DCM/MeOH/NH4OH 5/1/0.2) compound 27 (22 mg, 0.05 mmol, 75%) is 
obtained as a white solid. 
Data for compound 27: 
 29Dα                    14.63 (c 0.82, MeOH) 









pyrrol[1,2-b] isoxazole (21) 
 
To a solution of compound 22 (0.150 g, 0.41 mmol) in DMF (4 mL) NaN3 
(0.066g, 1.01 mmol) is added. The reaction mixture is stirred at 70°C for 3 h. 
After that time, the solvent is removed and the crude is dissolved in CH2Cl2, 
washed with water and brine. The organic phase is dried over Na2SO4, filtered and 
evaporated. The crude is then purified by a chromatography column on silica gel 
(Et2O/Cyhex 1/1) obtaining compound 21 (71 mg, 0.29 mmol, 73%) as a pale 
yellow oil.  
Data for compound 21: 
 30Dα                    -64.25 (c 0.93, CH2Cl2) 





H-NMR       (300 MHz, CDCl3, δ ppm, J Hz) 4.93 (dt, 1H, J 5-6=4.6, J 5-4=6.5,  H-
5), 4.57 (dd, 1H, J 4-3a= 2.5 , J 5-4= 6.5 H-4),  4.33 (ddd, 1H, J =4.27, J 3-2=6.9, J = 
11.03, H-2), 3.76 (dt, 1H J 4-3a=2.5, J 3-3a =6.9, H-3a), 3.40 (dd, 1H, J 8.1-2=6.53, J 
8.1-8.2=12.7, H-81), 3.34 (d, 2H, J 5-6=4.6, H-6), 3.19 (dd, 1H J 8.1-8.2= 12.7, J 8.2-
2=4.1, H-82), 2,26 (t, 2H, J3-3a = J 3-2=6.9, H-3), 1.51 (s, 3H, C(CH3)2), 1.31 (s, 3H, 
C(CH3)2). 
13
C-NMR      (75.4 MHz, CDCl3, δ ppm, J Hz) δ 113.2 (Cq C(CH3)2), 84.9 (CH, 
C-4),  80.6 (CH, C-5), 76.2 (CH, C-2), 71.3 (CH, C-3a), 60.6 (CH2, C-6), 53.7 










To a solution of 21 (47 mg, 0.20 mmol) in toluene (1.8 mL) 1-ethynyl-3,5-
bis(trifluoromethyl)benzene (71μL, 0.392 mmol), DIPEA (127 μL, 0.745 mmol,) 
and CuI (12 mg, 0.06 mmol) are added. The reaction mixture is stirred at 50 °C 
for 5 h, then 12 mL of a aqueous saturated solution of NaHCO3 is added and the 
mixture is extracted with EtOAc. The combined organic phase is dried over 
Na2SO4, filtered and concentrated. The crude is purified by column 
chromatography on silica gel (EtOAc/Cyhex 2/1) obtaining compound 37 (90 mg, 
0.19 mmol, 96%) as a white solid. 
Data for compound 37: 
 26Dα                    -50.43 (c 0.89, CH2Cl2) 











Following the general procedure for acidic deprotection on 37 (0.069 g, 0.15 
mmol), compound 20 (57 mg, 0.13mmol, 89%) is obtained as a white solid after 
purification through column chromatographic (DCM/MeOH/NH4OH 8/1/0.01). 
Data for compound 20: 
 30Dα                    -43.14 (c 0.935, CH2Cl2) 




H-NMR (300 MHz, MeOD, δ ppm, J Hz) δ 8.59  (s, 1H, H-5‟), 8.45 (s, 2H, H-2”, 
H-6”), 7.93 (s, 1H, H-4‟‟), 4.71-4.49 (m, 3H, H-8 and H-2), 4.30 (q, 1H, J4-5=J5-
6=5.0, H-5), 3.95 (t, 1H, J4-5=J4-3a=5.0 H-4), 3.71-3.62 (m, 1H, H-3a), 3.37-3.23 
(m, 2H, H-6), 2.40 (ddd, 1H, J1= 3.2, J2=6.3, J3.1-3.2=12.9, H-31), 2.33-2.21 (m, 
1H, H-32). 
13
C-NMR (75.4 MHz, MeOD, δ ppm, J Hz) δ  145.9 (Cq, C-4‟), 134.6 (Cq, C-
1‟‟), 133.5 (q, Cq, JCF=37, C-3”, C-5”), 126,7 (m, CH, C-2‟‟, C-6‟‟), 124.9 (CH, 
C-5‟), 124.8 (q, JCF=270, CF3), 122.3 (m, CH, C-4‟‟), 77.9 (CH, C-4), 76.8 (CH, 










A mixture of diol 23 (645 mg, 2.13 mmol), PPh3 (2.250 g, 8.50 mmol) and 
imidazole (0.579 g, 8.50 mmol) are dissolved in dry toluene (34 mL). The solution 
is heated up to 80°C and I2 (1.619 g, 6.38 mmol) is added slowly. The reaction 
mixture is stirred at 80°C under inert atmosphere for 1h. Afterwards, the reaction 
mixture is left reaching r.t., 40 mL of cold Et2O are added and the flask is cooled 
down in the fridge. The crude is then filtered over celite and concentrated. Due to 
the quite volatile nature of the product, attention is advised. The crude is purified 
by column chromatography on silica gel (Et2O/CyHex 1/2) and compound 38 (214 












To a solution of 38 (0.337 g, 1.25 mmol) in dry CH2Cl2 (7.2 mL), TFA (1.8 mL) is 
added dropwise. The solution is stirred at r.t. under inert atmosphere during 2.5 h. 
After that time, the mixture is concentrated and dried under vacuum. The crude 
product is dissolved in CH2Cl2 and Et3N (348 μL, 2.506 mmol), HOBt·H2O 
(0.1919 g, 1.253 mmol), EDCI·HCl (0.240 g, 1.25 mmol) and 3-butenoic acid 
(107 μL, 1.253 mmol) are added. The reaction is stirred overnight at r.t. and under 
inert atmosphere. After that time, the mixture is washed once with HCl 0.5M, 
once with a aqueous saturated solution of NaHCO3 and once with brine. The 
organic phase is then dried over Na2SO4, filtered and concentrated. The crude is 
purified by  column chromatography on silica gel (AcOEt/CyHex 1/2) obtaining 
compound 24 (189 mg, 0.79 mmol, 63%), as a mixture of two stable rotamers, as 
a white solid. 
Data for compound 24: 
 30Dα                    26.22 (c 0.54, CH2Cl2) 








H-NMR       (300 MHz, CDCl3, δ ppm, J Hz) δ 6.05-5.88 (m, 1H, H-8), 5.83-5.64 
(m, 1H, H-10), 5.27-5.02 (m, 4H, H-9, H-11), 5.00-4.95 and 4.63-4.49 (m, 2H, H-
4, H-5), 4.78-4.69 (m, 1H, H-3), 4.24-3.29 (m, 2H, H-2), 3.20-2.94 (m, 2H, H-7), 
1.43 (s, 3H, C(CH3)2), 1.30 (s, 3H, C(CH3)2).  
 
13
C-NMR     (75.4 MHz, CDCl3, δ ppm, J Hz) δ 170.5 (C=O, C-6, maj.), 169.5 
(C=O, C-6, min.), 133.6 (CH, C-8, maj.), 132.8 (CH, C-8, min.), 131.4 (CH, C-10, 
maj.), 131.1 (CH, C-10, min.), 118.3 (CH, C-11*, min.) 118.0 (CH, C-11*, maj.), 
116.7 (CH, C-9*, maj.), 116.1 (CH, C-9*, min.), 112.0 (Cq, C(CH3)2, min. and 
maj.),  84.8 (CH, C-4*, maj.), 83.3 (CH, C-4*, min.), 79.4 (CH, C-3, min.), 78.1 
(CH, C-3, maj.), 66.2 (CH, C-5*, maj.), 64.1 (CH, C-5*, min.), 52.7 (CH2, C-2, 
min.), 51.2 (CH2, C-2, maj.), 40.1 (CH2, C-7, min.), 39.0 (CH2, C-7, maj.), 26.92 
(CH3, C(CH3)2, maj.), 26.88 (CH3, C(CH3)2, min.), 25.0 (CH3, C(CH3)2, maj.), 
24.9 (CH3, C(CH3)2, min.). 








To a solution of 24 (0.069 g, 0.29 mmol) in 10 mL of dry CH2Cl2 a solution of 
second generation Grubb‟s Catalyst (37 mg, 0.04 mmol) in CH2Cl2 is added. The 
reaction mixture is then heated at 60°C, and stirred overnight at reflux under inert 
atmosphere. Then, the reaction mixture is concentrated, and the crude is purified 
by column chromatography on silica gel (EtOAc/Cyhex 5/1). Compound 25 (45 
mg, 0.22 mmol, 74%) is obtained as a white solid. 
Data for compound 25: 
 26Dα                    -57.72 (c 0.605, CH2Cl2) 




H-NMR       (300 MHz, CDCl3, δ ppm, J Hz) δ 5.97 (d, 1H J= 10.3, H-8), 5.86-
5.78 (m, 1H, H-7), 4.72 (td, 1H, J3.1-2=2.5, J2-3.2=J1-2=6.5, H-2), 4.42 (dd 1H J3.2-
2=6.5, J3.1-3.2= 13.7, H-32), 4.23-4.30 (t, 1H, J1-2=J1-8a= 6.5 H-1), 4.07-3.97 (m, 1H, 
H-8a), 3.36 (dd, 1H, J3.1-2= 2.5, J3.1-3.2= 13.7, H-31), 3.01-2.79 (m, 2H, H-6), 1.54 
(s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2).  
13
C-NMR      (75.4 MHz, CDCl3, δ ppm, J Hz) δ 166.0 (C=O), 123.6 (CH, C-7), 
122.7(CH, C-8), 114.2 (Cq, C(CH3)2), 83.4 (CH, C-1), 76.8 (CH, C-2), 63.3 (CH, 





5.4 Biological evaluation tests  
The biological evaluation tests were performed by Dr Antonio J. Moreno Vargas, 
University of Seville, using the method described by Saul and cols.
35
 with p-
nitrophenylglycosides commercially available, appropriated for each enzyme. 
This compound could be used in this analysis because it mimics a substrate for 
this class of enzymes and the following reaction (Scheme 16) can take place:  
 
 
Scheme 16. Example of enzymatic cleavage of a p-nitrophenylglycoside. 
At pH=9,8 (pH value reached at the end of the enzymatic tests adding a solution 
of sodium borate) p-nitrophenol is considered completely deprotonated and the 
quantity of p-nitrophenate, which is intensely yellow, formed in each case can be 
measured through visible absorption spectroscopy at 405 nm. In this conditions, 
values of absorbance of the formed p-nitrophenate vary linearly with time of 
reaction and enzyme concentration. 
Percentages of inhibition can be obtained comparing absorbance values between 
experiments with and without the inhibitor, conducted in the same condition of 
temperature, time and pH. These experiments are conducted twice and the given 
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